Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease Tuesday July 10, 2007, 9:35 am ET Return to Homepage | See All News

Samaritan Pharmaceuticals Inc. (OTC BB:SPHC.OB), a developer of innovative drugs, is pleased to announce it has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in-vitro data and suggests Caprospinol may not only slow down Alzheimer's but may also reverse plaque-related brain injuries associated with the mind-robbing disease of Alzheimer's. The hallmark of Alzheimer's disease is plaque formation in areas of the brain that control memory and thinking skills. Plaque can cause swelling and bumps on nerve cells, making it hard or even impossible for the cells to communicate. While the cause of Alzheimer's disease still remains unknown, a growing number of researchers are indicating that plaque formation and accumulation may play a role. The study was conducted by Samaritan's collaborating researchers, including Dr. Laurent Lecanu and Dr. Vassilios Papadopoulos.

Animal Study Confirms Caprospinol's (SP-233) Ability to Clear Brain Plaque and Empower Rat Brain Cells to Recover Memory Function In Vivo 'Proof of Concept' Study Proposes Direct Correlation Between Removing Beta Amyloid Plaque and Memory Recovery

Abstract:

http://www.samaritanpharma.com/caprospinol_abstract.pdf

Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, ``Memory recovery in rats is a lot simpler than curing Alzheimer's disease in people but these study results are extremely encouraging. The rats tested with our proprietary Alzheimer's rat model took on features similar to the crippling dementia seen in a human's Alzheimer's brain, and then, by treating the rats with Caprospinol, the rat's brain cells bounced back with complete memory.''

Samaritan Pharmaceuticals:
“Transforming Today’s Science Into Tomorrow’s Cures…”

Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company, focused on commercializing innovative therapeutic products to relieve the suffering of patients with Alzheimer's disease, Cancer, Cardiovascular disease, HIV, and Hepatitis-C. Samaritan, in collaboration with Pharmaplaz, Ireland, is advancing SP-01A, an “oral” HIV viral-entry inhibitor, to late stage clinical trials in Europe since it has completed Phase IIb clinical studies with positive results in the US. Samaritan has three drug candidates in nonclinical studies to develop IND applications, it’s building upon the IND application for Caprospinol, SP-233, to treat Alzheimer's disease patients; evaluating the use of SP-1000 for acute coronary disease patients; and the use of SP-10T1 as an "oral treatment" for Hepatitis-C patients. In addition, Samaritan has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and/or various Eastern European countries.

Please register so we can notify you of upcoming conference calls, news and events: CLICK HERE TO REGISTER NOW

Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.